Potentiation of anticancer agent cytotoxicity against sensitive and resistant AKR leukemia by amphotericin B1.
Amphotericin B was able to enhance the effects of actinomycin D (Act-D), adriamycin, and vincristine against AKR leukemia. AKR leukemia lines of increasing resistance to Act-D were obtained by passage in syngeneic mice treated with Act-D. The cells selected for Act-D resistance also eventually became cross-resistant to vincristine and Adriamycin, but resistance to these agents developed at a slower rate. Amphotericin B enhanced the effects of all these agents against the resistant cells, although the degree of enhancement varied among these antitumor agents and decreased as drug resistance increased in the late-passage leukemia lines.
D000666:Amphotericin B / Q000008:administration & dosage*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002470:Cell Survival / Q000187:drug effects; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D008806:Mice, Inbred AKR; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D003609:Dactinomycin; D014750:Vincristine; D000666:Amphotericin B; D004317:Doxorubicin